Type 2 Inflammatie Symposium: Beyond Boundaries in Respiratory Care
Sanofi
Type 2 Inflammatie Symposium: Beyond Boundaries in Respiratory Care
KlaslokaalDit symposium, gericht op KNO-artsen en longartsen, biedt een uitgebreide verkenning van de nieuwste ontwikkelingen in de behandeling en pathofysiologie van Type 2-inflammatie. Op 7 november 2024 delen vooraanstaande experts de meest recente inzichten en behandelstrategieën voor aandoeningen zoals ernstige astma en CRSwNP (chronische rhinosinusitis met nasale poliepen). De tweede dag, 8 november 2024, biedt optionele workshops waarin deelnemers praktische vaardigheden kunnen ontwikkelen en casuïstiek kunnen bespreken met collega-experts. Deze dag is een unieke kans om diepgaand inzicht te krijgen in specifieke patiëntprofielen en behandelingsmethoden.
Leerdoelen:
- Inzicht krijgen in de laatste ontdekkingen op het gebied van Type 2-inflammatie pathofysiologie.
- Behandeling van de nieuwste inzichten in de onderliggende mechanismen van Type 2-inflammatie en hoe deze bijdragen aan aandoeningen zoals ernstige astma en CRSwNP.
- Beoordelen van de huidige evidence en doelstellingen voor remissie van ernstige astma en CRSwNP.
- Begrijpen van de huidige standaarden voor de behandeling van deze aandoeningen en de mogelijkheden voor remissie.
- Selectie en gebruik van biologics bij Type 2-inflammatie.
- Leren hoe en wanneer verschillende biologics moeten worden ingezet bij patiënten met Type 2-inflammatie om de behandelingsresultaten te optimaliseren.
- Verbetering van de samenwerking tussen de bovenste en onderste luchtwegen in de klinische praktijk.
- Inzicht in hoe integrale benaderingen tussen KNO-artsen en longartsen kunnen leiden tot betere patiëntresultaten door samenwerking tussen de bovenste en onderste luchtwegen.
- Praktische toepassing en casuïstiek in workshops.
- Deelname aan interactieve workshops met een focus op mucus plugs, luchtwegremodelering, endoscopische scoresystemen, en patiëntprofilering in ernstige astma en CRSwNP.
Competenties
Sprekers
Vibeke Backer, MD, DMSc, is a Chief Respiratory Physician at Rigshospitalet, Copenhagen University, specializing in obstructive lung diseases, respiratory allergies, and lung cancer. With over 30 years of experience, she has made significant contributions to asthma, allergy, inflammation, and chronic rhinosinusitis research, publishing extensively with over 405 publications and an H-index of 50.
Gert-Jan Braunstahl is a Pulmonologist at Franciscus Gasthuis & Vlietland, specializing in respiratory medicine. He has made significant contributions to advancing asthma research and treatment, particularly in integrating the "united airways" concept into clinical practice and exploring the clinical applications of fractionated nitric oxide (FeNO) in respiratory allergy. Dr. Braunstahl has published extensively on these topics and is actively involved in research on morbid obesity and asthma, aging-related changes in the asthmatic lung, bacterial lysates for asthma exacerbation prevention, and clinical studies on biological therapies for asthma management. Additionally, he holds a position as an Associate Professor at Erasmus MC and serves as the Secretary of the Allergy and Immunology Interest Group at the European Respiratory Society.
Dr Lehtimäki works as a consultant at Allergy Centre, Tampere University Hospital and as Professor of Respiratory Medicine at Faculty of Medicine and Health Technology, Tampere University, Finland. His main clinical interests are difficult to treat and severe asthma. His research focuses on epidemiology, diagnostics and treatment of asthma and other inflammatory airway diseases. Dr Lehtimäki is a member of the steering committee of ISAR (International Severe Asthma Registry), National Centres Lead in ERS Clinical Research Collaboration SHARP (Severe Heterogenous Asthma Research collaboration, Patient-centered) and co-chair of the Nordic Severe Asthma Network.
Dr. Reitsma is an ENT physician at the Amsterdam UMC and is a globally recognized leader in Chronic Rhinosinusitis with Nasal Polyposis and and sinus and skull base surgery with more than 85 research publications. His expertise lies in understanding mucosal pathology in the upper and lower airways, with a particular focus on precision medicine. Dr. Reitsma's research encompasses diverse areas such as quality of life assessments, treatment outcomes, and economic considerations, aiming to improve patient care on individual and societal levels. A distinguishing aspect of Dr. Reitsma's work is his exploration of treatable traits and endotyping within CRSwNP. Through a combination of basic immunological research, epidemiological studies, and clinical trials, he seeks to uncover the underlying mechanisms of this condition and develop personalized treatment approaches. Recognizing the importance of real-world evidence, Dr. Reitsma leads as project leader initiatives like the Dutch Polyposis Registry (PolyREG), gathering data on the effects of biological treatments on CRSwNP. His leadership in such endeavors underscores his commitment to evidence-based practice and collaborative research efforts. Dr. Reitsma's influence extends internationally through collaborations with organizations like the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA). These partnerships facilitate global knowledge exchange and advancements in diagnostic and therapeutic strategies for CRSwNP. Moreover, Dr. Reitsma's expertise in biologic treatments highlights his status as a leading authority in the field. His insights inform clinical practice guidelines and enhance patient care pathways, reflecting his dedication to advancing medical science and improving patient outcomes.
Competenties
Sprekers
Vibeke Backer, MD, DMSc, is a Chief Respiratory Physician at Rigshospitalet, Copenhagen University, specializing in obstructive lung diseases, respiratory allergies, and lung cancer. With over 30 years of experience, she has made significant contributions to asthma, allergy, inflammation, and chronic rhinosinusitis research, publishing extensively with over 405 publications and an H-index of 50.
Gert-Jan Braunstahl is a Pulmonologist at Franciscus Gasthuis & Vlietland, specializing in respiratory medicine. He has made significant contributions to advancing asthma research and treatment, particularly in integrating the "united airways" concept into clinical practice and exploring the clinical applications of fractionated nitric oxide (FeNO) in respiratory allergy. Dr. Braunstahl has published extensively on these topics and is actively involved in research on morbid obesity and asthma, aging-related changes in the asthmatic lung, bacterial lysates for asthma exacerbation prevention, and clinical studies on biological therapies for asthma management. Additionally, he holds a position as an Associate Professor at Erasmus MC and serves as the Secretary of the Allergy and Immunology Interest Group at the European Respiratory Society.
Dr Lehtimäki works as a consultant at Allergy Centre, Tampere University Hospital and as Professor of Respiratory Medicine at Faculty of Medicine and Health Technology, Tampere University, Finland. His main clinical interests are difficult to treat and severe asthma. His research focuses on epidemiology, diagnostics and treatment of asthma and other inflammatory airway diseases. Dr Lehtimäki is a member of the steering committee of ISAR (International Severe Asthma Registry), National Centres Lead in ERS Clinical Research Collaboration SHARP (Severe Heterogenous Asthma Research collaboration, Patient-centered) and co-chair of the Nordic Severe Asthma Network.
Dr. Reitsma is an ENT physician at the Amsterdam UMC and is a globally recognized leader in Chronic Rhinosinusitis with Nasal Polyposis and and sinus and skull base surgery with more than 85 research publications. His expertise lies in understanding mucosal pathology in the upper and lower airways, with a particular focus on precision medicine. Dr. Reitsma's research encompasses diverse areas such as quality of life assessments, treatment outcomes, and economic considerations, aiming to improve patient care on individual and societal levels. A distinguishing aspect of Dr. Reitsma's work is his exploration of treatable traits and endotyping within CRSwNP. Through a combination of basic immunological research, epidemiological studies, and clinical trials, he seeks to uncover the underlying mechanisms of this condition and develop personalized treatment approaches. Recognizing the importance of real-world evidence, Dr. Reitsma leads as project leader initiatives like the Dutch Polyposis Registry (PolyREG), gathering data on the effects of biological treatments on CRSwNP. His leadership in such endeavors underscores his commitment to evidence-based practice and collaborative research efforts. Dr. Reitsma's influence extends internationally through collaborations with organizations like the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA). These partnerships facilitate global knowledge exchange and advancements in diagnostic and therapeutic strategies for CRSwNP. Moreover, Dr. Reitsma's expertise in biologic treatments highlights his status as a leading authority in the field. His insights inform clinical practice guidelines and enhance patient care pathways, reflecting his dedication to advancing medical science and improving patient outcomes.